Researchers to examine the role of pharmaceutically assisted lifestyle changes that support lifelong weight management.
Loma Linda University is participating in a study that will involve the use of the anti-diabetic medication Semaglutide to address health disparities in the Hispanic/Latino population.
Semaglutide 2.4 mg has demonstrated a 14.9% average weight loss in five multinational, multi-site studies of one or more years.
To recruit and reach the local Latino community, Loma Linda University is collaborating with the local nonprofit organization El Sol Neighborhood Educational Center and its Community Health Workers (CHW), which have successfully assisted Loma Linda University research and clinical projects in the past.
One hundred participants are randomized to receive a self-administered weekly Semaglutide 2.4 mg or placebo injection for six months. All participants also receive Intensive Lifestyle support using the Latino-adapted Full Plate diet. Individuals participate with personal and virtual visits, instruction and support for sleep hygiene, stress control, and exercise.
Each month, the study participants and their assigned CHW will visit the School of Public Health’s Nutrition Research Center (NCR) where nutrition instruction will be provided by the Dietician department of the School of Allied Health Professions. Coordination of services with the El Sol organization will be provided by the School of Behavioral Health.
In addition to these academic and community resources, churches associated with the Southeastern California Conference of Seventh-day Adventists have committed to the promotion of the LSS project.
Loma Linda University is anticipating that similar weight management results will occur in its Latino study population and that it will lead to a higher participation in medical weight management services. Genomic studies have not previously been conducted with the use of this class of glucagon-like peptide (GLP-1) medications.
By demonstrating potential genomic pathways, Loma Linda University researchers may be able to better address the epidemic and biological features of the disease of obesity.
The university-wide Latino Semaglutide Study is funded by Novo Nordisk, the Denmark-based maker of the drug.
